Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.85
-1.6%
$1.15
$0.61
$3.95
$27.05M0.163.84 million shs457,998 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$9.89
-1.1%
$8.68
$1.80
$20.63
$91.51M-0.721.89 million shs54,869 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.22
+0.7%
$2.68
$0.90
$3.35
$83.31M-0.1165,141 shs9,014 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.38
0.0%
$0.38
$0.26
$1.07
$86.97M1.332.81 million shs235,614 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+17.50%+93.81%+112.89%-56.42%
CervoMed Inc. stock logo
CRVO
CervoMed
+0.10%-0.99%+1.52%+33.87%-37.42%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-1.75%-5.39%-32.87%-5.79%+117.33%
Vaxart, Inc. stock logo
VXRT
Vaxart
-1.30%+0.40%0.00%-24.62%-57.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.85
-1.6%
$1.15
$0.61
$3.95
$27.05M0.163.84 million shs457,998 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$9.89
-1.1%
$8.68
$1.80
$20.63
$91.51M-0.721.89 million shs54,869 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.22
+0.7%
$2.68
$0.90
$3.35
$83.31M-0.1165,141 shs9,014 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.38
0.0%
$0.38
$0.26
$1.07
$86.97M1.332.81 million shs235,614 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+17.50%+93.81%+112.89%-56.42%
CervoMed Inc. stock logo
CRVO
CervoMed
+0.10%-0.99%+1.52%+33.87%-37.42%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-1.75%-5.39%-32.87%-5.79%+117.33%
Vaxart, Inc. stock logo
VXRT
Vaxart
-1.30%+0.40%0.00%-24.62%-57.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
3.00
Buy$9.00386.49% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.78
Moderate Buy$19.2995.00% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00216.03% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$2.00426.45% Upside

Current Analyst Ratings Breakdown

Latest ALLR, VXRT, CRVO, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
CervoMed Inc. stock logo
CRVO
CervoMed
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$11.00
8/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $31.00
8/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00 ➝ $16.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$10.00 ➝ $15.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
7/29/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$21.00 ➝ $27.00
7/28/2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$9.00
7/25/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
6/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/A$4.50 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.16) per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M1.84N/AN/A$0.26 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$4.71MN/A0.00N/AN/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)

Latest ALLR, VXRT, CRVO, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$0.21-$0.15+$0.06-$0.15N/AN/A
8/8/2025Q2 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.31
2.31
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
8.20
8.20
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
0.40
0.40
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.01%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1014.62 million14.62 millionNot Optionable
CervoMed Inc. stock logo
CRVO
CervoMed
49.25 million5.98 millionNot Optionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
737.61 million22.39 millionNot Optionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.94 million222.37 millionOptionable

Recent News About These Companies

Vaxart Announces Adjournment of Special Meeting of Stockholders
Vaxart Granted Extension by Nasdaq to Regain Compliance
Vaxart Discusses Reverse Stock Split Proposal
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.85 -0.03 (-1.60%)
As of 01:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$9.89 -0.11 (-1.10%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$2.22 +0.02 (+0.68%)
As of 01:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.38 0.00 (-0.03%)
As of 01:37 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.